HIGHBuilt-inPipeline
abdakibart (AVTX-009)
“10-K Item 1A: 'We are substantially dependent on the success of abdakibart (AVTX-009)'”
AVTX · Concentration risk · 10-K extracted
Avalo Therapeutics (AVTX) concentration risks
Updated
The most significant concentration Avalo Therapeutics discloses is abdakibart (AVTX-009), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Avalo Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH3
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
single CDMO
“10-K Item 1: 'We currently rely on a single CDMO to manufacture clinical supply for abdakibart (AVTX-009).'”
HIGHOutside partyCounterparty
Eli Lilly and Company
“10-K Item 1: 'Abdakibart (AVTX-009) is subject to a world-wide exclusive license from Eli Lilly and Company ("Lilly")'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Avalo Therapeutics' risk profile mirrors a common clinical-stage pattern: heavy reliance on one asset compounded by dependencies on the parties needed to develop and sell it. The company is substantially dependent on the success of abdakibart (AVTX-009), a structural concentration that means its investment case is effectively a single-molecule bet rather than a diversified portfolio. That dependency is reinforced on the manufacturing side, where the company currently relies on a single CDMO to manufacture clinical supply for abdakibart (AVTX-009) — any disruption at that one contract manufacturer would directly threaten the clinical timeline. On the intellectual-property side, abdakibart (AVTX-009) is subject to a world-wide exclusive license from Eli Lilly and Company, meaning continued rights to develop and commercialize the asset depend on that single counterparty relationship remaining intact. All three exposures are flagged at a high share of overall risk and none offer diversification to lean on. Together they describe a business whose verdict rises or falls almost entirely with abdakibart (AVTX-009): the Lilly license and CDMO dependencies are the mechanisms through which an otherwise strong clinical result could still be disrupted by a counterparty-level failure.
For the engine’s reasoning on AVTX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AVTX● | Avalo Therapeutics, Inc. | 3 | 0 | 0 | 3 |
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.